Dr James Wilmott

Research Associate
Melanoma Institute Australia, Central Clinical School

Telephone +61 02 9515 7840

Map

Current research students

Project title Research student
Biomarkers of response and resistance to anti-PD1 immunotherapy in melanoma. Tuba GIDE
Role of natural killer cells in patients with metastatic melanoma treated with immune checkpoint inhibitors Hansol LEE

Keywords

Genetics; Melanoma and skin cancer; Cancer

Clinical Specialty

Oncology

Selected grants

2016

  • 2016 NSW Premier's Awards for Outstanding Cancer Research - The 'Wildfire' Highly Cited Publication Award; Wilmott J; Cancer Institute New South Wales/NSW Premier's Awards for Outstanding Cancer Research.

Selected publications

Download citations: PDF RTF Endnote

Journals

  • De Paoli-Iseppi, R., Johansson, P., Menzies, A., Dias, K., Pupo, G., Kakavand, H., Wilmott, J., Mann, G., Hayward, N., Dinger, M., Long, G., Scolyer, R. (2016). Comparison of whole-exome sequencing of matched fresh and formalin fixed paraffin embedded melanoma tumours: implications for clinical decision making. Pathology, 48(3), 261-266. [More Information]
  • Fox, C., Lambie, D., Wilmott, J., Pinder, A., Pavey, S., Le Cao, K., Akalin, T., Karaarslan, I., Ozdemir, F., Scolyer, R., et al (2016). Multiparameter analysis of naevi and primary melanomas identifies a subset of naevi with elevated markers of transformation. Pigment Cell & Melanoma Research, 29(4), 885-898. [More Information]
  • Madore, J., Strbenac, D., Vilain, R., Menzies, A., Yang, J., Thompson, J., Long, G., Mann, G., Scolyer, R., Wilmott, J. (2016). PD-L1 Negative Status is Associated with Lower Mutation Burden, Differential Expression of Immune-Related Genes, and Worse Survival in Stage III Melanoma. Clinical Cancer Research, 22(15), 3915-3923. [More Information]
  • Madore, J., Strbenac, D., Vilain, R., Menzies, A., Yang, J., Thompson, J., Long, G., Mann, G., Scolyer, R., Wilmott, J. (2016). PD-L1 negative status is associated with lower mutation burden, differential expression of immune-related genes, and worse survival in stage-III melanoma. Clinical Cancer Research, 22(15), 3915-3923. [More Information]
  • Bosisio, F., Wilmott, J., Volders, N., Mercier, M., Wouters, J., Stas, M., Blokx, W., Massi, D., Thompson, J., Scolyer, R., et al (2016). Plasma cells in primary melanoma. Prognostic significance and possible role of IgA. Modern Pathology, 29(4), 347-358. [More Information]
  • Beckers, R., Selinger, C., Vilain, R., Madore, J., Wilmott, J., Harvey, K., Holliday, A., Cooper, C., Robbins, E., Gillett, D., Kennedy, C., Gluch, L., Carmalt, H., Warrier, S., Gee, H., Chan, C., McLean, A., Walker, E., McNeil, C., Beith, J., Scolyer, R., O'Toole, S., et al (2016). Programmed death ligand 1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome. Histopathology, 69(1), 25-34. [More Information]
  • Kakavand, H., Wilmott, J., Long, G., Scolyer, R. (2016). Targeted therapies and immune checkpoint inhibitors in the treatment of metastatic melanoma patients: a guide and update for pathologists. Pathology, 48(2), 194-202. [More Information]
  • Menzies, A., Wilmott, J., Drummond, M., Lo, S., Lyle, M., Chan, M., Thompson, J., Guminski, A., Carlino, M., Scolyer, R., Kefford, R., Long, G. (2015). Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors. Cancer, 121(21), 3826-3835. [More Information]
  • Heinemann, A., Cullinane, C., De Paoli-Iseppi, R., Wilmott, J., Gunatilake, D., Madore, J., Strbenac, D., Yang, J., Gowrishankar, K., Tiffen, J., Hersey, P., Gallagher, S., et al (2015). Combining BET and HDAC inhibitors synergistically induces apoptosis of melanoma and suppresses AKT and YAP signaling. Oncotarget, 6(25), 21507-21521.
  • Holtkamp, L., Wang, S., Wilmott, J., Madore, J., Vilain, R., Thompson, J., Nieweg, O., Scolyer, R. (2015). Detailed Pathological Examination of Completion Node Dissection Specimens and Outcome in Melanoma Patients with Minimal (<01 mm) Sentinel Lymph Node Metastases. Annals of Surgical Oncology, 22(9), 2972-2977. [More Information]
  • Kiyohara, E., Donovan, N., Takeshima, L., Huang, S., Wilmott, J., Scolyer, R., Jones, P., Somers, E., O’Shannessy, D., Hoon, D. (2015). Endosialin Expression in Metastatic Melanoma Tumor Microenvironment Vasculature: Potential Therapeutic Implications. Cancer Microenvironment, 8(2), 111-118. [More Information]
  • Wilmott, J., Colebatch, A., Kakavand, H., Shang, P., Carlino, M., Thompson, J., Long, G., Scolyer, R., Hersey, P. (2015). Expression of the class 1 histone deacetylases HDAC8 and 3 are associated with improved survival of patients with metastatic melanoma. Modern Pathology, 28(7), 884-894. [More Information]
  • Chi, M., Guo, S., Wilmott, J., Guo, X., Yan, X., Wang, C., Liu, X., Jin, L., Tseng, H., Liu, T., Scolyer, R., et al (2015). INPP4B is upregulated and functions as an oncogenic driver through SGK3 in a subset of melanomas. Oncotarget, 6(37), 39891-39907. [More Information]
  • Kakavand, H., Wilmott, J., Menzies, A., Vilain, R., Haydu, L., Yearley, J., Thompson, J., Kefford, R., Hersey, P., Long, G., Scolyer, R. (2015). PD-L1 expression and tumor-infiltrating lymphocytes define different subsets of MAPK inhibitor treated melanoma patients. Clinical Cancer Research, 21(14), 3140-3148. [More Information]
  • Madore, J., Vilain, R., Menzies, A., Kakavand, H., Wilmott, J., Hyman, J., Yearley, J., Kefford, R., Thompson, J., Long, G., Hersey, P., Scolyer, R. (2015). PD-L1 expression in melanoma shows marked heterogeneity within and between patients: Implications for anti-PD-1/PD-L1 clinical trials. Pigment Cell & Melanoma Research, 28(3), 245-253. [More Information]
  • Sanborn, J., Chung, J., Purdom, E., Wang, N., Kakavand, H., Wilmott, J., Butler, T., Thompson, J., Mann, G., Haydu, L., Saw, R., Scolyer, R., et al (2015). Phylogenetic analyses of melanoma reveal complex patterns of metastatic dissemination. Proceedings of the National Academy of Sciences of the United States of America (PNAS), 112(35), 10995-11000. [More Information]
  • Arafeh, R., Qutob, N., Emmanuel, R., Keren-Paz, A., Madore, J., Elkahloun, A., Wilmott, J., Gartner, J., Di Pizio, A., Winograd-Katz, S., Mann, G., Scolyer, R., et al (2015). Recurrent inactivating RASA2 mutations in melanoma. Nature Genetics, 47(12), 1408-1410. [More Information]
  • Liu, X., Lai, F., Yan, X., Jiang, C., Guo, S., Wang, C., Croft, A., Tseng, H., Wilmott, J., Scolyer, R., et al (2015). RIP1 Kinase Is an Oncogenic Driver in Melanoma. Cancer Research, 75(8), 1736-1748. [More Information]
  • Wilmott, J., Hersey, P., Long, G., Scolyer, R. (2015). Synergistic effects of MAPK and immune checkpoint inhibitors in melanoma: what is the best combination strategy? Melanoma Management, 19(3), 269-272. [More Information]
  • Kakavand, H., Vilain, R., Wilmott, J., Burke, H., Yearley, J., Thompson, J., Hersey, P., Long, G., Scolyer, R. (2015). Tumor PD-L1 expression, immune cell correlates and PD-1+ lymphocytes in sentinel lymph node melanoma metastases. Modern Pathology, 28(12), 1535-1544. [More Information]
  • Wilmott, J., Field, M., Johansson, P., Kakavand, H., Shang, P., De Paoli-Iseppi, R., Vilain, R., Pupo, G., Tembe, V., Jakrot, V., Thompson, J., Mann, G., Scolyer, R., et al (2015). Tumour procurement, DNA extraction, coverage analysis and optimisation of mutation-detection algorithms for human melanoma genomes. Pathology, 47(7), 683-693. [More Information]
  • Wong, S., Waldeck, K., Vergara, I., Schroder, J., Madore, J., Wilmott, J., Colebatch, A., De Paoli-Iseppi, R., Li, J., Lupat, R., Hruby, G., Mann, G., Thompson, J., Scolyer, R., Gill, A., et al (2015). UV-Associated Mutations Underlie the Etiology of MCV-Negative Merkel Cell Carcinomas. Cancer Research, 75(24), 5228-5234. [More Information]
  • Vilain, R., Wilmott, J., Scolyer, R. (2014). A light shines on melanoma metastagenesis. Pigment Cell & Melanoma Research, 25(7), 696-697. [More Information]
  • Kakavand, H., Crainic, O., Lum, T., O'Toole, S., Kefford, R., Thompson, J., Wilmott, J., Long, G., Scolyer, R. (2014). Concordant BRAFV600E mutation status in primary melanomas and associated naevi: implications for mutation testing of primary melanomas. Pathology, 46(3), 193-198. [More Information]
  • Marzese, D., Scolyer, R., Roqué, M., Vargas-Roig, L., Huynh, J., Wilmott, J., Murali, R., Buckland, M., Barkhoudarian, G., Thompson, J., et al (2014). DNA methylation and gene deletion analysis of brain metastases in melanoma patients identifies mutually exclusive molecular alterations. Neuro-Oncology, 16(11), 1499-1509. [More Information]
  • Wilmott, J., Haydu, L., Menzies, A., Lum, T., Hyman, J., Thompson, J., Hersey, P., Kefford, R., Scolyer, R., Long, G. (2014). Dynamics of chemokine, cytokine, and growth factor serum levels in BRAF-mutant melanoma patients during BRAF inhibitor treatment. The Journal of Immunology, 192(5), 2505-2513. [More Information]
  • Hersey, P., Kakavand, H., Wilmott, J., van der Westhuizen, A., Gallagher, S., Gowrishankar, K., Scolyer, R. (2014). How Anti PD1 Treatments are Changing the Management Of Melanoma. Melanoma Management, 1(2), 165-172. [More Information]
  • Menzies, A., Wilmott, J., Long, G., Scolyer, R. (2014). Intra-patient heterogeneity of BRAF mutation status: fact or fiction? British Journal of Cancer, 111(8), 1678-1679. [More Information]
  • Menzies, A., Lum, T., Wilmott, J., Hyman, J., Kefford, R., Thompson, J., O'Toole, S., Long, G., Scolyer, R. (2014). Intrapatient Homogeneity of BRAFV600E Expression in Melanoma. The American Journal of Surgical Pathology, 38(3), 377-382. [More Information]
  • Liu, Y., Lai, F., Wilmott, J., Yan, X., Liu, X., Luan, Q., Guo, S., Jiang, C., Tseng, H., Scolyer, R., et al (2014). Noxa upregulation by oncogenic activation of MEK/ERK through CREB promotes autophagy in human melanoma cells. Oncotarget, 5(22), 11237-11251.
  • Dong, L., Jin, L., Tseng, H., Wang, C., Wilmott, J., Yosufi, B., Yan, X., Jiang, C., Jiang, C., Scolyer, R., et al (2014). Oncogenic suppression of PHLPP1 in human melanoma. Oncogene, 33(39), 4756-4766. [More Information]
  • Sutton, S., Koach, J., Tan, O., Liu, B., Carter, D., Wilmott, J., Yosufi, B., Haydu, L., Mann, G., Thompson, J., Long, G., Scolyer, R., et al (2014). TRIM16 inhibits proliferation and migration through regulation of interferon beta 1 in melanoma cells. Oncotarget, 5(20), 10127-10139.
  • Mann, G., Pupo, G., Campain, A., Carter, C., Schramm, S., Pianova, S., Gerega, S., Desilva, C., Lai, K., Wilmott, J., Hersey, P., Kefford, R., Thompson, J., Yang, J., Scolyer, R., et al (2013). BRAF Mutation, NRAS Mutation, and the Absence of an Immune-Related Expressed Gene Profile Predict Poor Outcome in Patients with Stage III Melanoma. Journal of Investigative Dermatology, 133(2), 509-517. [More Information]
  • Wilmott, J., Menzies, A., Haydu, L., Capper, D., Preusser, M., Zhang, Y., Thompson, J., Kefford, R., von Diemling, A., Scolyer, R., Long, G. (2013). BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma. British Journal of Cancer, 108(4), 924-931. [More Information]
  • Long, G., Wilmott, J., Haydu, L., Tembe, V., Sharma, R., Rizos, H., Thompson, J., Howle, J., Scolyer, R., Kefford, R. (2013). Effects of BRAF inhibitors on human melanoma tissue before treatment, early during treatment and on progression. Pigment Cell & Melanoma Research, 26(4), 499-508. [More Information]
  • Long, G., Wilmott, J., Capper, D., Preusser, M., Zhang, Y., Thompson, J., Kefford, R., von Deimling, A., Scolyer, R. (2013). Immunohistochemistry Is Highly Sensitive and Specific for the Detection of V600E BRAF Mutation in Melanoma. The American Journal of Surgical Pathology, 37(1), 61-65. [More Information]
  • Ye, Y., Jin, L., Wilmott, J., Hu, W., Yosufi, B., Thorne, R., Liu, T., Rizos, H., Yan, X., Dong, L., Hersey, P., Scolyer, R., et al (2013). PI(4,5)P2 5-phosphatase A regulates PI3K/Akt signalling and has a tumour suppressive role in human melanoma. Nature Communications, 4, 1-15. [More Information]
  • Wilmott, J., Haydu, L., Bagot, M., Zhang, Y., Jakrot, V., McCarthy, S., Lugassy, C., Thompson, J., Scolyer, R., Jakrot, V., et al (2012). Angiotropism is an independent predictor of microscopic satellites in primary cutaneous melanoma. Histopathology, 61(5), 889-898. [More Information]
  • Wilmott, J., Scolyer, R., Long, G., Hersey, P. (2012). Combined targeted therapy and immunotherapy in the treatment of advanced melanoma. OncoImmunology, 1(6), 997-999. [More Information]
  • Wilmott, J., Tembe, V., Howle, J., Sharma, R., Thompson, J., Rizos, H., Lo, R., Kefford, R., Scolyer, R., Long, G. (2012). Intratumoral Molecular Heterogeneity in a BRAF-Mutant, BRAF Inhibitor-Resistant Melanoma: A Case Illustrating the Challenges for Personalized Medicine. Molecular Cancer Therapeutics, 11(12), 2704-2708. [More Information]
  • Shayan, R., Karnezis, T., Murali, R., Wilmott, J., Ashton, M., Taylor, G., Thompson, J., Hersey, P., Achen, M., Scolyer, R., et al (2012). Lymphatic vessel density in primary melanomas predicts sentinel lymph node status and risk of metastasis. Histopathology, 61(4), 702-710. [More Information]
  • Wilmott, J., Long, G., Howle, J., Haydu, L., Sharma, R., Thompson, J., Kefford, R., Hersey, P., Scolyer, R. (2012). Selective BRAF inhibitors induce marked T - cell infiltration into human metastatic melanoma. Clinical Cancer Research, 18(5), 1386-1394. [More Information]
  • Cheung, B., Koach, J., Tan, O., Kim, P., Bell, J., D'andreti, C., Sutton, S., Malyukova, A., Sekyere, E., Norris, M., Wilmott, J., Cooper, C., Halliday, G., Scolyer, R., et al (2012). The retinoid signalling molecule, TRIM16, is repressed during squamous cell carcinoma skin carcinogenesis in vivo and reduces skin cancer cell migration in vitro. Journal of Pathology, 226(3), 451-462. [More Information]
  • Jin, L., Hu, W., Jiang, C., Wang, J., Han, C., Chu, P., Zhang, L., Thorne, R., Wilmott, J., Scolyer, R., Hersey, P., et al (2011). MicroRNA-149*, a p53-responsive microRNA, functions as an oncogenic regulator in human melanoma. Proceedings of the National Academy of Sciences of the United States of America (PNAS), 108(38), 15840-15845. [More Information]
  • Wilmott, J., Zhang, X., Hersey, P., Scolyer, R. (2011). The emerging important role of microRNAs in the pathogenesis, diagnosis and treatment of human cancers. Pathology, 43(6), 657-671. [More Information]
  • Busam, K., Murali, R., Pulitzer, M., McCarthy, S., Thompson, J., Shaw, H., Brady, M., Coit, D., Dusza, S., Wilmott, J., Scolyer, R., et al (2009). Atypical Spitzoid Melanocytic Tumors With Positive Sentinel Lymph Nodes in Children and Teenagers, and Comparison With Histologically Unambiguous and Lethal Melanomas. American Journal of Surgical Pathology, 33(9), 1386-1395. [More Information]
  • Shingde, M., Buckland,, M., Busam, K., McCarthy, S., Wilmott, J., Thompson, J., Scolyer, R. (2009). Primary cutaneous Ewing sarcoma/primitive neuroectodermal tumour: a clinicopathological analysis of seven cases highlighting diagnostic pitfalls and the role of FISH testing in diagnosis. Journal of Clinical Pathology, 62(10), 915-919. [More Information]
  • Howman-Giles, R., Shaw, H., Scolyer, R., Murali, R., Wilmott, J., McCarthy, S., Uren, R., Thompson, J. (2009). Sentinel Lymph Node Biopsy in Pediatric and Adolescent Cutaneous Melanoma Patients. Annals of Surgical Oncology, 17(1), 138-143. [More Information]

Conferences

  • Tallapragada, V., Wilmott, J., Pilowsky, P., Goodchild, A. (2008). A1 and C1 Neurons in the rat brainstem show different profiles of G-a MRNA expression. Australian Neuroscience Society Annul Meeting (2008), Hobart: Australian Neuroscience Society.

2016

  • De Paoli-Iseppi, R., Johansson, P., Menzies, A., Dias, K., Pupo, G., Kakavand, H., Wilmott, J., Mann, G., Hayward, N., Dinger, M., Long, G., Scolyer, R. (2016). Comparison of whole-exome sequencing of matched fresh and formalin fixed paraffin embedded melanoma tumours: implications for clinical decision making. Pathology, 48(3), 261-266. [More Information]
  • Fox, C., Lambie, D., Wilmott, J., Pinder, A., Pavey, S., Le Cao, K., Akalin, T., Karaarslan, I., Ozdemir, F., Scolyer, R., et al (2016). Multiparameter analysis of naevi and primary melanomas identifies a subset of naevi with elevated markers of transformation. Pigment Cell & Melanoma Research, 29(4), 885-898. [More Information]
  • Madore, J., Strbenac, D., Vilain, R., Menzies, A., Yang, J., Thompson, J., Long, G., Mann, G., Scolyer, R., Wilmott, J. (2016). PD-L1 Negative Status is Associated with Lower Mutation Burden, Differential Expression of Immune-Related Genes, and Worse Survival in Stage III Melanoma. Clinical Cancer Research, 22(15), 3915-3923. [More Information]
  • Madore, J., Strbenac, D., Vilain, R., Menzies, A., Yang, J., Thompson, J., Long, G., Mann, G., Scolyer, R., Wilmott, J. (2016). PD-L1 negative status is associated with lower mutation burden, differential expression of immune-related genes, and worse survival in stage-III melanoma. Clinical Cancer Research, 22(15), 3915-3923. [More Information]
  • Bosisio, F., Wilmott, J., Volders, N., Mercier, M., Wouters, J., Stas, M., Blokx, W., Massi, D., Thompson, J., Scolyer, R., et al (2016). Plasma cells in primary melanoma. Prognostic significance and possible role of IgA. Modern Pathology, 29(4), 347-358. [More Information]
  • Beckers, R., Selinger, C., Vilain, R., Madore, J., Wilmott, J., Harvey, K., Holliday, A., Cooper, C., Robbins, E., Gillett, D., Kennedy, C., Gluch, L., Carmalt, H., Warrier, S., Gee, H., Chan, C., McLean, A., Walker, E., McNeil, C., Beith, J., Scolyer, R., O'Toole, S., et al (2016). Programmed death ligand 1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome. Histopathology, 69(1), 25-34. [More Information]
  • Kakavand, H., Wilmott, J., Long, G., Scolyer, R. (2016). Targeted therapies and immune checkpoint inhibitors in the treatment of metastatic melanoma patients: a guide and update for pathologists. Pathology, 48(2), 194-202. [More Information]

2015

  • Menzies, A., Wilmott, J., Drummond, M., Lo, S., Lyle, M., Chan, M., Thompson, J., Guminski, A., Carlino, M., Scolyer, R., Kefford, R., Long, G. (2015). Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors. Cancer, 121(21), 3826-3835. [More Information]
  • Heinemann, A., Cullinane, C., De Paoli-Iseppi, R., Wilmott, J., Gunatilake, D., Madore, J., Strbenac, D., Yang, J., Gowrishankar, K., Tiffen, J., Hersey, P., Gallagher, S., et al (2015). Combining BET and HDAC inhibitors synergistically induces apoptosis of melanoma and suppresses AKT and YAP signaling. Oncotarget, 6(25), 21507-21521.
  • Holtkamp, L., Wang, S., Wilmott, J., Madore, J., Vilain, R., Thompson, J., Nieweg, O., Scolyer, R. (2015). Detailed Pathological Examination of Completion Node Dissection Specimens and Outcome in Melanoma Patients with Minimal (<01 mm) Sentinel Lymph Node Metastases. Annals of Surgical Oncology, 22(9), 2972-2977. [More Information]
  • Kiyohara, E., Donovan, N., Takeshima, L., Huang, S., Wilmott, J., Scolyer, R., Jones, P., Somers, E., O’Shannessy, D., Hoon, D. (2015). Endosialin Expression in Metastatic Melanoma Tumor Microenvironment Vasculature: Potential Therapeutic Implications. Cancer Microenvironment, 8(2), 111-118. [More Information]
  • Wilmott, J., Colebatch, A., Kakavand, H., Shang, P., Carlino, M., Thompson, J., Long, G., Scolyer, R., Hersey, P. (2015). Expression of the class 1 histone deacetylases HDAC8 and 3 are associated with improved survival of patients with metastatic melanoma. Modern Pathology, 28(7), 884-894. [More Information]
  • Chi, M., Guo, S., Wilmott, J., Guo, X., Yan, X., Wang, C., Liu, X., Jin, L., Tseng, H., Liu, T., Scolyer, R., et al (2015). INPP4B is upregulated and functions as an oncogenic driver through SGK3 in a subset of melanomas. Oncotarget, 6(37), 39891-39907. [More Information]
  • Kakavand, H., Wilmott, J., Menzies, A., Vilain, R., Haydu, L., Yearley, J., Thompson, J., Kefford, R., Hersey, P., Long, G., Scolyer, R. (2015). PD-L1 expression and tumor-infiltrating lymphocytes define different subsets of MAPK inhibitor treated melanoma patients. Clinical Cancer Research, 21(14), 3140-3148. [More Information]
  • Madore, J., Vilain, R., Menzies, A., Kakavand, H., Wilmott, J., Hyman, J., Yearley, J., Kefford, R., Thompson, J., Long, G., Hersey, P., Scolyer, R. (2015). PD-L1 expression in melanoma shows marked heterogeneity within and between patients: Implications for anti-PD-1/PD-L1 clinical trials. Pigment Cell & Melanoma Research, 28(3), 245-253. [More Information]
  • Sanborn, J., Chung, J., Purdom, E., Wang, N., Kakavand, H., Wilmott, J., Butler, T., Thompson, J., Mann, G., Haydu, L., Saw, R., Scolyer, R., et al (2015). Phylogenetic analyses of melanoma reveal complex patterns of metastatic dissemination. Proceedings of the National Academy of Sciences of the United States of America (PNAS), 112(35), 10995-11000. [More Information]
  • Arafeh, R., Qutob, N., Emmanuel, R., Keren-Paz, A., Madore, J., Elkahloun, A., Wilmott, J., Gartner, J., Di Pizio, A., Winograd-Katz, S., Mann, G., Scolyer, R., et al (2015). Recurrent inactivating RASA2 mutations in melanoma. Nature Genetics, 47(12), 1408-1410. [More Information]
  • Liu, X., Lai, F., Yan, X., Jiang, C., Guo, S., Wang, C., Croft, A., Tseng, H., Wilmott, J., Scolyer, R., et al (2015). RIP1 Kinase Is an Oncogenic Driver in Melanoma. Cancer Research, 75(8), 1736-1748. [More Information]
  • Wilmott, J., Hersey, P., Long, G., Scolyer, R. (2015). Synergistic effects of MAPK and immune checkpoint inhibitors in melanoma: what is the best combination strategy? Melanoma Management, 19(3), 269-272. [More Information]
  • Kakavand, H., Vilain, R., Wilmott, J., Burke, H., Yearley, J., Thompson, J., Hersey, P., Long, G., Scolyer, R. (2015). Tumor PD-L1 expression, immune cell correlates and PD-1+ lymphocytes in sentinel lymph node melanoma metastases. Modern Pathology, 28(12), 1535-1544. [More Information]
  • Wilmott, J., Field, M., Johansson, P., Kakavand, H., Shang, P., De Paoli-Iseppi, R., Vilain, R., Pupo, G., Tembe, V., Jakrot, V., Thompson, J., Mann, G., Scolyer, R., et al (2015). Tumour procurement, DNA extraction, coverage analysis and optimisation of mutation-detection algorithms for human melanoma genomes. Pathology, 47(7), 683-693. [More Information]
  • Wong, S., Waldeck, K., Vergara, I., Schroder, J., Madore, J., Wilmott, J., Colebatch, A., De Paoli-Iseppi, R., Li, J., Lupat, R., Hruby, G., Mann, G., Thompson, J., Scolyer, R., Gill, A., et al (2015). UV-Associated Mutations Underlie the Etiology of MCV-Negative Merkel Cell Carcinomas. Cancer Research, 75(24), 5228-5234. [More Information]

2014

  • Vilain, R., Wilmott, J., Scolyer, R. (2014). A light shines on melanoma metastagenesis. Pigment Cell & Melanoma Research, 25(7), 696-697. [More Information]
  • Kakavand, H., Crainic, O., Lum, T., O'Toole, S., Kefford, R., Thompson, J., Wilmott, J., Long, G., Scolyer, R. (2014). Concordant BRAFV600E mutation status in primary melanomas and associated naevi: implications for mutation testing of primary melanomas. Pathology, 46(3), 193-198. [More Information]
  • Marzese, D., Scolyer, R., Roqué, M., Vargas-Roig, L., Huynh, J., Wilmott, J., Murali, R., Buckland, M., Barkhoudarian, G., Thompson, J., et al (2014). DNA methylation and gene deletion analysis of brain metastases in melanoma patients identifies mutually exclusive molecular alterations. Neuro-Oncology, 16(11), 1499-1509. [More Information]
  • Wilmott, J., Haydu, L., Menzies, A., Lum, T., Hyman, J., Thompson, J., Hersey, P., Kefford, R., Scolyer, R., Long, G. (2014). Dynamics of chemokine, cytokine, and growth factor serum levels in BRAF-mutant melanoma patients during BRAF inhibitor treatment. The Journal of Immunology, 192(5), 2505-2513. [More Information]
  • Hersey, P., Kakavand, H., Wilmott, J., van der Westhuizen, A., Gallagher, S., Gowrishankar, K., Scolyer, R. (2014). How Anti PD1 Treatments are Changing the Management Of Melanoma. Melanoma Management, 1(2), 165-172. [More Information]
  • Menzies, A., Wilmott, J., Long, G., Scolyer, R. (2014). Intra-patient heterogeneity of BRAF mutation status: fact or fiction? British Journal of Cancer, 111(8), 1678-1679. [More Information]
  • Menzies, A., Lum, T., Wilmott, J., Hyman, J., Kefford, R., Thompson, J., O'Toole, S., Long, G., Scolyer, R. (2014). Intrapatient Homogeneity of BRAFV600E Expression in Melanoma. The American Journal of Surgical Pathology, 38(3), 377-382. [More Information]
  • Liu, Y., Lai, F., Wilmott, J., Yan, X., Liu, X., Luan, Q., Guo, S., Jiang, C., Tseng, H., Scolyer, R., et al (2014). Noxa upregulation by oncogenic activation of MEK/ERK through CREB promotes autophagy in human melanoma cells. Oncotarget, 5(22), 11237-11251.
  • Dong, L., Jin, L., Tseng, H., Wang, C., Wilmott, J., Yosufi, B., Yan, X., Jiang, C., Jiang, C., Scolyer, R., et al (2014). Oncogenic suppression of PHLPP1 in human melanoma. Oncogene, 33(39), 4756-4766. [More Information]
  • Sutton, S., Koach, J., Tan, O., Liu, B., Carter, D., Wilmott, J., Yosufi, B., Haydu, L., Mann, G., Thompson, J., Long, G., Scolyer, R., et al (2014). TRIM16 inhibits proliferation and migration through regulation of interferon beta 1 in melanoma cells. Oncotarget, 5(20), 10127-10139.

2013

  • Mann, G., Pupo, G., Campain, A., Carter, C., Schramm, S., Pianova, S., Gerega, S., Desilva, C., Lai, K., Wilmott, J., Hersey, P., Kefford, R., Thompson, J., Yang, J., Scolyer, R., et al (2013). BRAF Mutation, NRAS Mutation, and the Absence of an Immune-Related Expressed Gene Profile Predict Poor Outcome in Patients with Stage III Melanoma. Journal of Investigative Dermatology, 133(2), 509-517. [More Information]
  • Wilmott, J., Menzies, A., Haydu, L., Capper, D., Preusser, M., Zhang, Y., Thompson, J., Kefford, R., von Diemling, A., Scolyer, R., Long, G. (2013). BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma. British Journal of Cancer, 108(4), 924-931. [More Information]
  • Long, G., Wilmott, J., Haydu, L., Tembe, V., Sharma, R., Rizos, H., Thompson, J., Howle, J., Scolyer, R., Kefford, R. (2013). Effects of BRAF inhibitors on human melanoma tissue before treatment, early during treatment and on progression. Pigment Cell & Melanoma Research, 26(4), 499-508. [More Information]
  • Long, G., Wilmott, J., Capper, D., Preusser, M., Zhang, Y., Thompson, J., Kefford, R., von Deimling, A., Scolyer, R. (2013). Immunohistochemistry Is Highly Sensitive and Specific for the Detection of V600E BRAF Mutation in Melanoma. The American Journal of Surgical Pathology, 37(1), 61-65. [More Information]
  • Ye, Y., Jin, L., Wilmott, J., Hu, W., Yosufi, B., Thorne, R., Liu, T., Rizos, H., Yan, X., Dong, L., Hersey, P., Scolyer, R., et al (2013). PI(4,5)P2 5-phosphatase A regulates PI3K/Akt signalling and has a tumour suppressive role in human melanoma. Nature Communications, 4, 1-15. [More Information]

2012

  • Wilmott, J., Haydu, L., Bagot, M., Zhang, Y., Jakrot, V., McCarthy, S., Lugassy, C., Thompson, J., Scolyer, R., Jakrot, V., et al (2012). Angiotropism is an independent predictor of microscopic satellites in primary cutaneous melanoma. Histopathology, 61(5), 889-898. [More Information]
  • Wilmott, J., Scolyer, R., Long, G., Hersey, P. (2012). Combined targeted therapy and immunotherapy in the treatment of advanced melanoma. OncoImmunology, 1(6), 997-999. [More Information]
  • Wilmott, J., Tembe, V., Howle, J., Sharma, R., Thompson, J., Rizos, H., Lo, R., Kefford, R., Scolyer, R., Long, G. (2012). Intratumoral Molecular Heterogeneity in a BRAF-Mutant, BRAF Inhibitor-Resistant Melanoma: A Case Illustrating the Challenges for Personalized Medicine. Molecular Cancer Therapeutics, 11(12), 2704-2708. [More Information]
  • Shayan, R., Karnezis, T., Murali, R., Wilmott, J., Ashton, M., Taylor, G., Thompson, J., Hersey, P., Achen, M., Scolyer, R., et al (2012). Lymphatic vessel density in primary melanomas predicts sentinel lymph node status and risk of metastasis. Histopathology, 61(4), 702-710. [More Information]
  • Wilmott, J., Long, G., Howle, J., Haydu, L., Sharma, R., Thompson, J., Kefford, R., Hersey, P., Scolyer, R. (2012). Selective BRAF inhibitors induce marked T - cell infiltration into human metastatic melanoma. Clinical Cancer Research, 18(5), 1386-1394. [More Information]
  • Cheung, B., Koach, J., Tan, O., Kim, P., Bell, J., D'andreti, C., Sutton, S., Malyukova, A., Sekyere, E., Norris, M., Wilmott, J., Cooper, C., Halliday, G., Scolyer, R., et al (2012). The retinoid signalling molecule, TRIM16, is repressed during squamous cell carcinoma skin carcinogenesis in vivo and reduces skin cancer cell migration in vitro. Journal of Pathology, 226(3), 451-462. [More Information]

2011

  • Jin, L., Hu, W., Jiang, C., Wang, J., Han, C., Chu, P., Zhang, L., Thorne, R., Wilmott, J., Scolyer, R., Hersey, P., et al (2011). MicroRNA-149*, a p53-responsive microRNA, functions as an oncogenic regulator in human melanoma. Proceedings of the National Academy of Sciences of the United States of America (PNAS), 108(38), 15840-15845. [More Information]
  • Wilmott, J., Zhang, X., Hersey, P., Scolyer, R. (2011). The emerging important role of microRNAs in the pathogenesis, diagnosis and treatment of human cancers. Pathology, 43(6), 657-671. [More Information]

2009

  • Busam, K., Murali, R., Pulitzer, M., McCarthy, S., Thompson, J., Shaw, H., Brady, M., Coit, D., Dusza, S., Wilmott, J., Scolyer, R., et al (2009). Atypical Spitzoid Melanocytic Tumors With Positive Sentinel Lymph Nodes in Children and Teenagers, and Comparison With Histologically Unambiguous and Lethal Melanomas. American Journal of Surgical Pathology, 33(9), 1386-1395. [More Information]
  • Shingde, M., Buckland,, M., Busam, K., McCarthy, S., Wilmott, J., Thompson, J., Scolyer, R. (2009). Primary cutaneous Ewing sarcoma/primitive neuroectodermal tumour: a clinicopathological analysis of seven cases highlighting diagnostic pitfalls and the role of FISH testing in diagnosis. Journal of Clinical Pathology, 62(10), 915-919. [More Information]
  • Howman-Giles, R., Shaw, H., Scolyer, R., Murali, R., Wilmott, J., McCarthy, S., Uren, R., Thompson, J. (2009). Sentinel Lymph Node Biopsy in Pediatric and Adolescent Cutaneous Melanoma Patients. Annals of Surgical Oncology, 17(1), 138-143. [More Information]

2008

  • Tallapragada, V., Wilmott, J., Pilowsky, P., Goodchild, A. (2008). A1 and C1 Neurons in the rat brainstem show different profiles of G-a MRNA expression. Australian Neuroscience Society Annul Meeting (2008), Hobart: Australian Neuroscience Society.

To update your profile click here. For support on your academic profile contact .